[Medical therapy of gastroesophageal reflux. Evaluation of the activity of clebopride by continuous intraluminal pH measurement].
Seven female and three male outpatients (mean age 45, range 37-54), suffering from gastroesophageal reflux underwent therapy with clebopride, a new selective antidopaminergic agent. Before and after treatment (1 mg b.i.d. for ten days) 24 h-continuous monitoring of esophageal pH was done. Clebopride significantly lowered the number and the extension of gastroesophageal acid refluxes.
Alvisi
V
V
Clinica Medica, Università di Ferrara.
Onofrio
W
W
Intrieri
L
L
D'Ambrosi
A
A
D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic
D000932:Antiemetics; D001549:Benzamides; C014417:clebopride
Terapia medica del reflusso gastroesofageo. Valutazione dell'attività della clebopride mediante pHmetria endoluminale continua.